<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126160</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH-2021-NPC01</org_study_id>
    <nct_id>NCT05126160</nct_id>
  </id_info>
  <brief_title>Immune Score Based Radiomics in Nasopharyngeal Carcinoma</brief_title>
  <official_title>Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In nasopharyngeal carcinoma (NPC), tumor, node and metastasis (TNM) staging system is the&#xD;
      main tool for determining treatment strategy and assessment of prognosis. However, the&#xD;
      prognoses of patients with the same TNM stage after similar treatment vary widely. The aim of&#xD;
      this study is to establish an immune score based radiomic staging system for NPC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2021</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>Median follow-up time of 5 years for the whole group</time_frame>
    <description>The AUC of the immune score based radiomic staging system</description>
  </primary_outcome>
  <enrollment type="Anticipated">494</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Immune Score Based Radiomics</intervention_name>
    <description>To establish an immune score based radiomic staging system for nasopharyngeal carcinoma</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-metastatic NPC patients receive radical radiotherapy with/without induction or&#xD;
        concurrent chemotherapy. De novo metastatic NPC patients would receive at least 4 cycles of&#xD;
        platinum-based therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with newly histologically confirmed non-keratinizing/keratinizing carcinoma.&#xD;
&#xD;
        ECOG Performance status: 0-1 With normal liver function test (ALT, AST ≤2.5ULN) Renal:&#xD;
        creatinine clearance ≥60ml/min Without hematopathy,marrow: WBC &gt;4*109/L, HGB&gt;90G/L, and&#xD;
        PLT&gt;100*109/L. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Contraindications for MRI scan Prior malignancy (except adequately treated carcinoma&#xD;
        in-situ of the cervix or · basal/squamous cell carcinoma of the skin) Previous chemotherapy&#xD;
        or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment&#xD;
        volume) Patient is pregnant or lactating Any severe intercurrent disease, which may bring&#xD;
        unacceptable risk or affect the compliance of the trial, for example, unstable cardiac&#xD;
        disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control&#xD;
        (fasting plasma glucose &gt;1.5×ULN), or emotional disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaozhong Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaozhong Chen</last_name>
    <phone>0571-88128202</phone>
    <phone_ext>+86</phone_ext>
    <email>cxzfyun@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangpan Li</last_name>
      <email>rm001227@whu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiangpan Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingqing Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo First Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Ningbo</state>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pengrong Lou</last_name>
    </contact>
    <investigator>
      <last_name>Pengrong Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianliang Zhou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Center Lihuili Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Ningbo</state>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miaozhen Lu</last_name>
      <email>lmz2005@yeah.net</email>
    </contact>
    <investigator>
      <last_name>Miaozhen Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanping Bei</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Wenzhou</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changlin Zou</last_name>
      <email>zcl19670115@163.com</email>
    </contact>
    <investigator>
      <last_name>Changlin Zou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raoying Xie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen</last_name>
      <phone>571-88128202</phone>
      <phone_ext>+86</phone_ext>
      <email>cxzfyun@sina.com</email>
    </contact>
    <investigator>
      <last_name>Caineng Cao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lei Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuang Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mengyun Qiang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

